BridgeBio Pharma to Participate in September Investor Events
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Ainylam Pharmaceuticals shares tumble following study results, BridgeBio Pharma rises
August 30, 2024 7:39 AM EDTAlnylam Pharma (NASDAQ: ALNY) shares tumbled 11.5% Friday following the release of results from its HELIOS-B Phase 3 study of vutrisiran, despite the study meeting all primary and secondary endpoints.
The investigational RNAi therapeutic, aimed at treating ATTR amyloidosis with cardiomyopathy (ATTR-CM), was shown to reduce the risk of death and cardiovascular events by 28% compared to placebo in the overall... More
